

**Avonex® Liquid (Interferon beta 1a)
Biogen Ltd**

(No. 58/03)

10 November, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following an abbreviated submission.

Accepted for restricted use within NHS Scotland.

Avonex is a liquid formulation which replaces a powder formulation of the same strength that requires reconstitution. It is supplied at the same price. This product is used for the treatment of selected ambulatory patients with relapsing-remitting multiple sclerosis under the provision of a risk-sharing scheme between the Scottish Executive and the manufacturer.

**Professor David H Lawson
Chairman**